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The effect of cetirizine, a histamine 1 receptor 
antagonist, on bone remodeling after calvarial 
suture expansion
Objective: The objective of this study was to evaluate the effects of cetirizine, 
a histamine 1 receptor antagonist, on bone remodeling after calvarial suture 
expansion. Methods: Sixty male Sprague–Dawley rats were divided into 4 
groups; the phosphate-buffered saline (PBS)-injected no expansion group, 
cetirizine-injected no expansion group, PBS-injected expansion group, and 
cetirizine-injected expansion group, and were observed at 7, 14, and 28 days. 
Five rats per group were examined at each observation day. Daily injections of 
cetirizine or PBS were administered to the relevant groups starting 2 weeks prior 
to expander insertion. A rapid expander was inserted in the calvarial bone to 
deliver 100 cN of force to the parietal suture. The specimens were prepared for 
hematoxylin and eosin and tartrate-resistant acid phosphatase (TRAP) staining. 
Suture opening and bone regeneration were evaluated using microcomputed 
tomography and bone histomorphometric analysis. Serum blood levels of 
osteocalcin and carboxy-terminal collagen crosslinks (CTX) were also evaluated. 
Results: TRAP-positive cell counts and CTX levels decreased while osteocalcin 
levels increased in the cetirizine-injected expansion group at observation day 28. 
In the expansion groups, the mineralized area gradually increased throughout 
the observation period. At day 28, the cetirizine-injected expansion group 
showed greater bone volume density, greater mineralized area, and narrower 
average suture width than did the PBS-injected expansion group. Conclusions: 
Cetirizine injection facilitated bone formation after suture expansion, mostly by 
suppressing osteoclastic activity. Histamine 1 receptor antagonists may aid in 
bone formation after calvarial suture expansion in the rat model.
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INTRODUCTION
Epidemiological studies have suggested a causative 
relationship between environmental pollution and the 
increased incidence of allergic conditions in the general 
population.1 Recently, several studies have shown an 
increase in atopic dermatitis and asthma in urban chil-
dren, and this has been associated with air pollution and 
proximity to traffic.2-5 Histamine is a major mediator in 
allergic diseases and atopic dermatitis, which are broadly 
managed by prescribing antihistamines for long dura-
tions.6,7
Histamine affects bone remodeling by modulating the 
osteoclastic pathway, which increases bone resorption.8,9 
Animal studies have shown that blocking the uptake of 
histamine by using histamine receptor antagonists de-
creases osteoclastic activity as well as bone resorption. 
In rats, histamine 1 receptor antagonists (H1RAs) have 
been shown to increase the mechanical properties of the 
bone by inhibiting bone resorption.10,11
Allergic rhinitis, which is mainly treated using anti-
histamines, commonly causes upper airway obstruction 
that is a significant risk factor for developing malocclu-
sion in children.12-14 The number of children with such 
allergic symptoms has increased continuously during 
the past years.15 Therefore, it is conceivable that children 
with different malocclusions may be taking antihista-
mines sometime during their orthodontic treatment. A 
previous study on rats also showed a decrease in alveolar 
bone resorption, which in turn decreased tooth move-
ment upon antihistamine injection.16 Young children 
with malocclusions often need dentofacial orthopedic 
treatment involving growth modification via craniofa-
cial suture expansion followed by new bone formation, 
which could be affected by antihistamine intake. There-
fore, the aim of this study was to evaluate the effects 
of cetirizine, a H1RA, on bone remodeling after calvarial 
suture expansion in rats.
MATERIALS AND METHODS
Animals
Sixty male Sprague–Dawley rats (weight, 280–315 
g; age, 8 weeks old) were housed in standard breeding 
cages under normal temperatures (22–24oC) and 12-
hour light/dark conditions, and were provided standard 
rat chow. The rats were randomly divided into four 
groups: phosphate-buffered saline (PBS)-injected no ex-
pansion, cetirizine-injected no expansion, PBS-injected 
expansion, and cetirizine-injected expansion (Figure 1). 
Five rats from each group were observed at 7, 14, and 
28 days, and were weighed at the beginning and end of 
the observation periods (Figure 2). All procedures in this 
animal study complied with the Guideline of the Asso-
ciation for Assessment and Accreditation of Laboratory 
Animal Care International, and were approved by the 
Institutional Animal Research Ethics Committee at the 
Yonsei Medical Center (IACUC Approval number, 2017-
0176).
Injection and expansion protocols
Cetirizine (10 mg/kg; Sigma-Aldrich, St. Louis, MO, 
USA) or PBS (10 mg/kg) was injected peritoneally on 
a daily basis to the relevant groups 2 weeks prior to 
expansion device insertion. The rapid expander was 
constructed using a stainless-steel round wire having 
Figure 1. Three-dimensional 
microcomputed tomography 
(micro-CT) reconstruction 
of the phosphate-buffered 
saline (PBS)/cetirizine groups 
after active expansion of the 
parietal suture at 7 (A, D), 
14 (B, E), and 28 (C, F) days. 
Parietal suture showing the 
region of interest (ROI) used 
in the micro-CT analysis (G). 
Parietal suture with the ex-
pansion appliance (H). Images 
of the PBS- and cetirizine-
injected no expansion groups 
(I, J).
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a diameter of 0.5 mm (remanium®; Dentaurum, Isprin-
gen, Germany). The device was designed to meet the 
dimensions of 10-mm width and 10-mm height with 1 
helical spring at the end when inactivated. To deliver 
the expansion force, the appliance was placed on a grid 
and the ends were expanded to deliver a force of 100 
cN (Figure 1). General anesthesia was administered for 
2 minutes by using 5% isoflurane (Ifran; Hana Pharm, 
Seoul, Korea) in oxygen (50 mg/kg), followed by an 
intraperitoneal injection of Zoletil 50 (Virbac, Carros, 
France) at 30 mg/kg and xylazine (Rompun®; Bayer 
Healthcare, Seoul, Korea) at 10 mg/kg of body weight. 
A high-speed 330 carbide bur of 0.8-mm diameter was 
used to drill a small hole on each side of the parietal 
bones in the calvarial bone with a 10-mm distance in 
between to fit the appliance in an inactivated state. 
Thereafter, the appliance was inserted either in an inac-
tive or expanded state. The helical spring was fixed with 
resin after insertion. Daily injections of cetirizine (Sigma-
Aldrich) at 10 mg/kg or PBS at 10 mg/kg were admin-
istered approximately at the same time throughout the 
7-, 14-, and 28-day periods. All animals were sacrificed 
after the experimental period on days 7, 14, and 28.
Tissue preparation and histomorphometric analysis
The rat calvarial bone was dissected on days 7, 14, 
and 28 to include the bilateral parietal bones, sagittal 
suture, and coronal suture (Figure 1). All specimens were 
fixed with 4% paraformaldehyde solution for 2 weeks 
after dissection. For hematoxylin and eosin staining 
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Figure 3. Changes of the suture on histological sections. Hematoxylin and eosin staining of the parietal suture. Seven-
day phosphate-buffered saline (PBS) no expansion (A), 7-day PBS expansion (A’), 14-day PBS no expansion (B), 14-day 
PBS expansion (B’), 28-day PBS no expansion (C), 28-day PBS expansion (C’), 7-day cetirizine no expansion (D), 7-day 
cetirizine expansion (D’), 14-day cetirizine no expansion (E), 14-day cetirizine expansion (E’), 28-day cetirizine no expan-
sion (F), and 28-day cetirizine expansion (F’). Scale bar = 100 µm.
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Figure 2. Effect of cetirizine/phosphate-buffered saline 
(PBS) and active/inactive expansion on body weight.
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Figure 5. Tartrate-resistant acid phosphatase (TRAP)-positive cell count comparison between the phosphate-buffered 
saline (PBS)- and cetirizine-injected rats in the no expansion and expansion groups. TRAP staining. Scale bar = 20 μm.
***p < 0.001. 
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Figure 4. Region of interest 
used in the histomorphomet-
ric analysis. Representations 
of the mineralized area (A), 
voided areas (B), and fibrous 
area (C). H&E staining (left, 
×20 magnification; right, ×40 
magnification). Scale bar = 
100 μm.
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(Sigma-Aldrich), the fixed specimens were decalcified 
with 10% ethylenediaminetetraacetic acid (pH 7.4) at 
4oC for 3 weeks, embedded in paraffin, and sectioned 
at a thickness of 4 µm (Figure 3). For tartrate-resistant 
acid phosphatase (TRAP) staining (Sigma-Aldrich), the 
sections were dewaxed, rehydrated, and incubated for 1 
hour at 37oC in the TRAP reagent.
For each specimen, 3 areas with a total area of 9 × 104 
µm2 were randomly selected with a region of interest at 
the center of the suture. Each area was analyzed using 
the MetaMorph software (Molecular Devices, Sunnyvale, 
CA, USA), and the results were averaged for obtaining 
the mineralized area (µm2), fibrous area (µm2), and min-
eralized/fibrous area ratio (Figure 4). The measurements 
were taken in reference to a previous study by Parfitt et 
al.17 TRAP-positive cell counts were performed on the 3 
selected areas and were averaged for each group (Figure 
5).
Microcomputed tomography
The samples were scanned using microcomputed to-
mography (micro-CT) (SkyScan 1173; Bruker, Kontich, 
Belgium) conducted at 130 kV and 60 µA with a pixel 
size of 30 µm. The region of interest was determined at 
2 mm from the coronal suture with a 4- × 4-mm-sized 
square area and a depth of 0.7 mm, including the sagit-
tal suture focused at the center (Figure 1).
The morphometric indices of the sagittal suture area 
were evaluated using the CTAn® software (SkyScan; 
Bruker) and the bone volume density (BV, mm3), bone/
tissue volume percentage (BV/TV, %), and average suture 
width (mm) were assessed. The average suture width was 
calculated using the following equation: 
Average suture width = [(total volume − bone volume) 
of the region of interest] / 4 / 0.7.
Enzyme-linked immunosorbent assay
Blood samples were collected from the lateral tail vein 
at 2 time points: at the day of expansion appliance in-
sertion and at the time of sacrifice on days 7, 14, and 
28. Serum was separated by centrifugation and stored at 
−80oC. Serum protein levels of osteocalcin and carboxy-
terminal collagen crosslinks (CTX) were measured using 
the osteocalcin enzyme-linked immunosorbent assay 
(ELISA) kit (MyBioSource, San Diego, CA, USA) and CTX 
ELISA kit (MyBioSource). Optical density was measured 
at a wavelength of 450 nm.
Statistical analysis
Statistical analysis was performed using SAS software 
ver. 9.4 (SAS Institute, Cary, NC, USA). The normality of 
the variables was tested using the Kolmogorov–Smirnov 
test. Descriptive statistics were represented as mean 
and standard deviation. Difference between groups was 
analyzed using one-way analysis of variance followed 
by post-hoc least significant difference tests. Statistical 
significance was set at p < 0.05.
Table 1. Comparison of bone volume (mm3), BV/TV (%), and suture width (mm)
Variable
No expansion Expansion
PBS Cetirizine p-value PBS Cetirizine p-value
Bone volume (mm3)
   7 days 4.08 ± 0.33 4.05 ± 0.48 0.902 3.08 ± 1.30 2.14 ± 0.64 0.074
   14 days 4.64 ± 0.43 4.55 ± 0.27 0.830 3.63 ± 0.84 3.36 ± 0.70 0.507
   28 days 5.90 ± 0.38 5.63 ± 0.37 0.575 4.77 ± 0.94 6.35 ± 0.62 0.004**
BV/TV (%)
   7 days 36.02 ± 2.89 35.47 ± 4.27 0.896 26.99 ± 11.25 21.93 ± 3.86 0.234
   14 days 40.92 ± 3.75 40.14 ± 2.36 0.830 32.06 ± 7.42 29.62 ± 6.16 0.507
   28 days 52.02 ± 3.38 49.77 ± 3.30 0.481 45.33 ± 4.44 55.64 ± 5.83 0.006**
Suture width (mm)
   7 days 0.27 ± 0.02 0.26 ± 0.02 0.688 0.30 ± 0.04 0.33 ± 0.02 0.091
   14 days 0.22 ± 0.02 0.24 ± 0.01 0.446 0.28 ± 0.03 0.31 ± 0.05 0.147
   28 days 0.19 ± 0.02 0.20 ± 0.01 0.330 0.23 ± 0.03 0.18 ± 0.02 0.004**
Values are presented as mean ± standard deviation.
Statistical significance were determined using the one-way analysis of variance followed by post-hoc least significant difference 
tests.
PBS, Phosphate-buffered saline; BV/TV, bone volume/tissue volume. 
**p < 0.01.
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RESULTS
The initial age and weight of the rats did not dif-
fer significantly among the groups. Rats with active 
expansion devices did not have a significant difference 
in weight compared to those with inactive expansion 
devices in both the PBS- and cetirizine-injected groups 
during all the observation periods. However, rats injected 
Table 2. Comparison of the mineralized area, fibrous area, and mineralized/fibrous area ratio in the no expansion group
Variable
No expansion
PBS Cetirizine p-value
Mineralized area (µm2)
   7 days 56,814.80 ± 5,832.85 59,291.40 ± 8,790.72 0.601
   14 days 57,632.80 ± 7,255.40 58,449.80 ± 9,094.42 0.887
   28 days 61,443.40 ± 2,846.19 69,432.60 ± 2,162.87 0.006**
Fibrous area (µm2)
   7 days 32,641.00 ± 7,116.59 31,729.00 ± 7,048.69 0.843
   14 days 31,953.20 ± 7,213.41 30,118.60 ± 8,765.01 0.735
   28 days 28,378.20 ± 2,569.25 19,601.40 ± 2,945.92 0.118
Mineralized/Fibrous area ratio
   7 days 1.82 ± 0.46 1.99 ± 0.71 0.546
   14 days 1.91 ± 0.57 2.03 ± 0.49 0.66
   28 days 2.18 ± 0.16 3.60 ± 0.50 0.007**
Values are presented as mean ± standard deviation.
Statistical significance were determined using the one-way analysis of variance followed by post-hoc least significant difference 
tests.
PBS, Phosphate-buffered saline. 
**p < 0.01.
Table 3. Comparison of the mineralized area, fibrous area, and mineralized/fibrous area ratio in the expnasion group 
Variable
Expansion
PBS Cetirizine p-value
Mineralized area (µm2)
   7 days 30,741.60 ± 5,589.90 29,223.60 ± 8,502.13 0.764
   14 days 43,503.60 ± 6,727.94 44,307.00 ± 11,862.81 0.889
   28 days 54,937.60 ± 1,531.63 68,903.80 ± 6,995.06 < 0.0001***
Fibrous area (µm2)
   7 days 58,772.80 ± 5,890.58 64,654.80 ± 8,369.56 0.212
   14 days 50,469.20 ± 7,777.17 52,475.40 ± 9,752.07 0.712
   28 days 43,230.20 ± 13,309.27 27,388.40 ± 9,447.69 0.009**
Mineralized/Fibrous area ratio
   7 days 0.53 ± 0.15 0.46 ± 0.17 0.805
   14 days 0.88 ± 0.20 0.88 ± 0.33 0.995
   28 days 1.36 ± 0.36 2.87 ± 1.32 0.005**
Values are presented as mean ± standard deviation.
Statistical significance were determined using the one-way analysis of variance followed by post-hoc least significant difference 
tests.
PBS, Phosphate-buffered saline. 
**p < 0.01, ***p < 0.001.
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with cetirizine weighed less at the 7- and 28-day obser-
vation periods (Figure 2).
In the expansion groups, the micro-CT images dis-
played suture closure via gradual bone formation during 
the 7-, 14-, and 28-day observation periods. At the 28-
day observation period, the cetirizine-injected expansion 
group had significantly greater BV and BV/TV as well as 
narrower average suture width than did the PBS-injected 
expansion group. No significant differences were ob-
served between the no expansion groups in BV, BV/TV, 
and average suture width during all the observation pe-
riods (Table 1).
On histological examination, the expansion groups 
showed expansion of the parietal suture with fibrous tis-
sue reoriented across the suture parallel to the direction 
of expansion, with immature woven bone at the suture 
margins; however, the no expansion groups showed no 
disruption of the sutural fibers and showed traces of 
only small amounts of new bone (Figure 3). Histomor-
phometric analysis of the parietal suture area showed 
a significantly smaller mineralized area in the expan-
sion groups than in the no expansion groups because 
of active expansion of the sutures. The mineralized area 
gradually increased in the expansion groups during the 
observation periods, and at the 28-day observation pe-
riod, the cetirizine-injected expansion group had a sig-
nificantly greater mineralized area and mineralized area/
fibrous area ratio than did the PBS-injected expansion 
group (Table 2, 3). The number of TRAP-positive cells at 
the 28-day observation period was smaller in the cetiri-
zine-injected expansion group than in the PBS-injected 
expansion group (Figure 5).
The cetirizine-injected groups had higher serum os-
teocalcin levels than did the PBS-injected groups at the 
14- and 28-day observation periods. At day 28, serum 
CTX levels were significantly lower in the cetirizine-in-
jected expansion group than in the PBS-injected expan-
sion group (Figure 6).
DISCUSSION
Sutures play an important role as growth sites in the 
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Figure 6. Comparison of osteocalcin and carboxy-terminal collagen crosslink (CTX) levels between the phosphate-buff-
ered saline (PBS)- and cetirizine-injected rats in the no expansion (A, B) and expansion (C, D) groups. 
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craniofacial region. Dentofacial orthopedic devices are 
designed to utilize the expansion potentials of the su-
tures to modify undesirable growth patterns and skeletal 
discrepancies. In such processes, mechanical stimuli are 
exerted on the sutures, and these activate the cellular 
growth responses in the sutures.18 Studies have shown 
that cartilaginous tissue proliferates and differentiates 
at the osteogenic layer in the bone fronts of the suture 
when mechanical expansion force is applied.19,20 Several 
animal studies have shown that tensional forces pro-
gressively widen the sutures and that cartilaginous tissue 
is replaced by new bone formation in irregular patterns 
that parallel the stretching force.21,22 In this study, the 
histological evaluations showed finger-like projections 
of new non-lamellar bone starting from the ends of the 
parietal bones and extending irregularly towards the 
center of the expanded sutures; this was similar to the 
findings of previous studies using expansion devices on 
rat sutures.21,23
Bone remodeling occurs via sequential steps that 
are mediated by osteoclasts resorbing old bone and 
osteoblasts depositing new bone. Histamine has been 
reported to promote osteoclastogenesis by acting on 
the differential expression of histamine receptors on os-
teoblasts and osteoclasts.24 A study on ovariectomized 
rats showed impaired bone resorption after histamine 
receptor antagonist treatment because of a decrease in 
both osteoclast recruitment and resorption.25 Likewise, 
many studies have evaluated different histamine recep-
tor antagonists and their effects on the balance of bone 
remodeling.10,26,27 In this study, the results of micro-CT 
and histomorphometric analysis showed a significant 
increase in BV, BV/TV percentage, mineralized area, and 
mineralized/fibrous area ratio in the cetirizine-injected 
expansion group, which was in line with those of a 
previous study by Meh et al.16 that showed an increase 
in alveolar BV at a late phase during orthodontic tooth 
movement due to cetirizine injections. 
Osteocalcin is a bone matrix protein synthesized by 
osteoblasts, and it is used as marker for bone forma-
tion.28 The blood serum osteocalcin levels were signifi-
cantly higher in the cetirizine-injected groups at days 14 
and 28, indicating active bone formation. During bone 
resorption, collagen fragments, such as serum CTX are 
generated, and CTX is used as a marker for osteoclastic 
activity.29 CTX level was significantly lower in the cetiri-
zine-injected expansion group than in the PBS-injected 
expansion group at day 28. A decrease in the TRAP-
positive cell count on day 28 in the cetirizine-injected 
expansion group was also noted, which was in line with 
the systematic effect of cetirizine observed via the blood 
serum CTX levels. An increase in osteocalcin and de-
crease in CTX levels as well as a decrease in the TRAP-
positive cell count on day 28 in the cetirizine-injected 
expansion group also support the micro-CT findings 
showing higher bone volumes at day 28 after cetirizine 
injection.
This study calculated the average suture width by 
subtracting the bone volume from the total volume in 
the region of interest. This method was used because 
of the irregular shape of the cranial suture, which is a 
limitation of this study in terms of comparing the actual 
amount of suture expansion at a specific point. When 
using this method, the average suture width was not 
significantly different between the cetirizine- and PBS-
injected expansion groups at day 7, suggesting that 
even though the animals were preinjected with cetirizine 
or PBS 2 weeks before expander insertion, an intake of 
antihistamines does not clearly affect the amount of 
rapid suture expansion. However, a significant increase 
was observed in bone formation at a microscopic level 
at day 28, which was most likely due to decreased bone 
resorption caused by a H1RA suppressing osteoclastic 
activity. The positive influence of cetirizine on new bone 
formation suggests that the use of a H1RA may be ben-
eficial in terms of bone formation after mechanically 
stimulated cranial suture expansion. Nevertheless, fur-
ther studies evaluating the influence of different catego-
ries and dosages of antihistamines on bone remodeling 
in the craniofacial suture region are needed for verifying 
the clinical significance of these findings.
CONCLUSION
This study observed the effects of cetirizine, a H1RA, 
on bone remodeling after suture expansion in rats. The 
main findings were as follows: 1) The amount of rapid 
suture expansion was not clearly affected by cetirizine 
administration. 2) Cetirizine increased bone formation 
in the expanded suture area at day 28 by suppressing 
osteoclast activity. 3) Intake of a H1RA may aid in bone 
formation after mechanical expansion of cranial sutures 
in the rat model.
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